Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) announced the publication of clinical outcomes in the Journal of Vascular Surgery for patients treated with Symvess™, their FDA-approved bioengineered human tissue vascular conduit. The study focused on 12 patients with hospital-acquired vascular complications from their V005 pivotal Phase 2/3 clinical trial.

Key results showed 92% secondary patency (blood flow) at an average follow-up of 23.3 months, with 100% limb salvage and zero conduit infections. The patients required arterial repair due to various complications including vascular interventions, tumor resections, and orthopedic surgery injuries. Symvess received full FDA approval in December 2024 for use in adults requiring urgent revascularization for extremity arterial injury.

Positive

• 92% secondary patency rate maintained over 23.3 months average follow-up
• 100% limb salvage rate achieved in all treated patients
• Zero confirmed infections of the conduit reported
• FDA full approval already secured in December 2024
• Addresses 30% of patients requiring vascular repair due to hospital complications

Negative

• Risk of graft failure including life-threatening hemorrhage (noted in boxed warning)
• Requires long-term antiplatelet therapy
• Risk of thrombosis in patients who discontinue antiplatelet therapy
• Potential risk of infectious disease transmission from manufacturing process

Insights

Medical Technology Expert

Humacyte's Symvess shows strong clinical outcomes in hospital-acquired vascular complications, validating its off-the-shelf bioengineered vessel technology.

Humacyte's published study in the Journal of Vascular Surgery demonstrates promising clinical outcomes for their FDA-approved Symvess bioengineered vessel in treating hospital-acquired vascular complications. The data from 12 patients showed 92% secondary patency (maintained blood flow), 100% limb salvage, and zero infections over an average 23.3-month follow-up period.

These results are particularly significant for several reasons. First, Symvess addresses the approximately 30% of vascular repairs stemming from iatrogenic injuries and surgical complications - a substantial but often overlooked patient population. Second, as an off-the-shelf solution, Symvess eliminates the need for saphenous vein harvesting, which creates additional surgical trauma and may not be feasible in emergency settings.

The acellular tissue engineered vessel (ATEV) technology represents a critical advancement over traditional options. Unlike synthetic grafts that carry infection risks, Symvess is bioengineered human tissue designed for universal compatibility. The FDA granted full approval in December 2024 specifically for extremity arterial injuries requiring urgent revascularization when autologous vein grafts aren't feasible.

This publication bolsters Humacyte's clinical evidence by focusing on hospital-acquired complications, expanding beyond the traditional trauma applications. The positive outcomes in patients with iatrogenic injuries, arterial excisions during tumor resections, steal syndrome, and orthopedic surgery complications demonstrate versatility across multiple clinical scenarios.

While the sample size is modest (12 patients), the extended follow-up period and consistent outcomes across multiple complication types suggest Symvess could become a valuable tool in the vascular surgeon's arsenal, particularly in time-sensitive cases where harvesting autologous vessels would create additional patient harm or delay critical treatment.

- Results were published in the Journal of Vascular Surgery -

- Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures -

- Patients treated with Symvess were observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection -

DURHAM, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced publication of outcomes for patients with hospital-acquired vascular complications treated with Symvess in the Journal of Vascular Surgery. The publication, titled "Bioengineered Human Blood Vessels to Treat Hospital-Acquired Vascular Complications," reported that "Symvess was observed to have high levels of patency, 100% limb salvage, and zero cases of conduit infection in 12 patients with hospital-acquired iatrogenic injuries or complications of vascular surgical procedures."

"Vascular complications of medical or surgical procedures aren't as widely publicized as injuries from accidental trauma or violence, but the end result - a complex surgical problem - is the same," from Rishi Kundi, MD, RPVI, FACS, FSVS, Chief of Vascular Trauma at the R Adams Cowley Shock Trauma Center of the University of Maryland. "Our goal is to preserve life and limb. The value of Symvess lies in sparing the patient the additional surgical time of saphenous vein harvest while still avoiding the use of a plastic artificial vessel. Having Symvess as a readily available option is a tremendous advantage when a surgeon needs to perform emergency repair of arterial injuries resulting from another procedure."

Complications of surgery and vascular procedures, including iatrogenic injuries, planned oncological tumor resections, and steal syndrome following arteriovenous access placement, are increasingly common in modern medical care and are reported to comprise close to 30% of patients requiring vascular repair. Harvesting of autologous vein to address these consequences and complications produces injury to the patient, and suitable vein may not be accessible in the urgent/emergent setting. Symvess, or the ATEV™ (acellular tissue engineered vessel-tyod), is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. Symvess is available off the shelf and does not require further injuring the patient to obtain a vascular conduit. The U.S. Food and Drug Administration (FDA) granted full approval for Symvess in December 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

The publication describes the outcomes of 12 patients with hospital-acquired iatrogenic injuries or complications of vascular surgical procedures. The 12 patients were a subgroup from Humacyte’s V005 pivotal Phase 2/3 clinical study conducted in the U.S. and Israel, and the results have not been published previously. The 12 patients required arterial repair or replacement due to damage from vascular interventions to treat peripheral artery disease, arterial excisions during tumor resections, steal syndrome, and injury during orthopedic surgery. At end of follow up (average follow-up time of 23.3 months) 11 of 12 (92%) of patients retained secondary patency (blood flow). None of the patients suffered an amputation, and there were zero confirmed infections of the conduit.

“Patients experiencing hospital-acquired vascular complications represent a meaningful but often forgotten subset of vascular trauma patients,” said Shamik Parikh, MD, Chief Medical Officer of Humacyte. “The patient outcomes observed in this study show that Symvess can provide limb salvage and durable patency in patients experiencing iatrogenic injury or complications from surgery or vascular procedures.”

INDICATION

Symvess is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of Symvess integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use Symvess in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. 

WARNINGS AND PRECAUTIONS

• Graft Rupture
  
  

Vascular graft rupture has occurred in patients treated with Symvess. Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

• Anastomotic Failure
  
  

Anastomotic failure has occurred in patients treated with Symvess. In clinical studies of Symvess, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin.

• Thrombosis
  
  

Thrombosis has occurred in patients treated with Symvess. In clinical trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with Symvess.

• Transmission of Infectious Diseases
  
  

Symvess is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of Symvess are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum). The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular graft thrombosis, pyrexia (fever) and pain.

Please see full Prescribing Information at www.symvess.com, including Boxed Warning, for Symvess.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

What are the clinical trial results for Humacyte's Symvess vascular conduit (HUMA)?

In a 12-patient study, Symvess demonstrated 92% secondary patency over 23.3 months average follow-up, with 100% limb salvage and zero conduit infections in treating hospital-acquired vascular complications.

When did the FDA approve Humacyte's Symvess and what is its indication?

The FDA granted full approval in December 2024 for Symvess use in adults as a vascular conduit for extremity arterial injury requiring urgent revascularization when autologous vein graft isn't feasible.

What are the main risks associated with Humacyte's Symvess treatment?

Key risks include graft failure leading to potential life-threatening hemorrhage, anastomotic failure, thrombosis risk (requiring long-term antiplatelet therapy), and potential infectious disease transmission from the manufacturing process.

How does Symvess address hospital-acquired vascular complications?

Symvess provides an off-the-shelf bioengineered solution that eliminates the need for harvesting patient's own veins, particularly beneficial in urgent/emergent settings where suitable veins may not be accessible.

What percentage of vascular repairs are due to hospital-acquired complications?

According to the press release, close to 30% of patients requiring vascular repair are due to complications of surgery and vascular procedures, including iatrogenic injuries, planned oncological tumor resections, and steal syndrome.